A 67-year-old man, 15 years post–living related kidney transplant developed a cutaneous squamous cell carcinoma (SCC). Surveillance positron emission tomography/computed tomography scan for SCC identified an ischial bone lesion. Immunoglobulin A λ paraproteins were found on serum protein electrophoresis/urine protein electrophoresis. Bone marrow biopsy and aspirate were normocellular, but displayed multifocal clusters of large binucleated and multinucleated plasma cells with variable histiocytoid or Hodgkin/Reed-Sternberg cell–like cytomorphology (panel A [hematoxylin and eosin stain, original magnification ×1000]; panels B-C [Wright-Giemsa stain, original magnification ×500]), ∼20% of marrow cellularity, and immunophenotype: CD45, CD138+ (panel D; CD138 stain, original magnification ×500), CD19, CD20, CD117, CD27+, CD28+, CD56(weak)+ (panel E; CD56 stain, original magnification ×500), cyclin D1 and CD30, with λ light-chain restriction (panel F; in situ hybridization for lambda mRNA stain, original magnification ×500). Epstein-Barr virus (EBV)-encoded RNA–in situ hybridization was negative. Fluorescence in situ hybridization analysis revealed monosomy 13, loss of 1 copy of the immunoglobulin heavy chain gene, and 1q21 (CKS1B) gain; subclones showed monosomy 17 and 1p32 (CDKN2C) deletion.

This case represents a monomorphic posttransplant lymphoproliferative disorder (PTLD)–plasma cell myeloma (PCM), which accounts for ∼5% of all PTLD (prevalence ∼1/1000 solid organ transplant recipients). Posttransplant (PT)-PCM usually occurs late after transplantation, in older individuals (median age, 60 years), recipients of deceased donor allografts, and in those having received antithymocyte globulin therapy. Most are EBV and cytogenetic abnormalities are similar to immunocompetent multiple myeloma. Reduction of immunosuppression is not efficacious in PT-PCM, but use of modern myeloma therapeutic regimens has led to significantly improved outcomes.

A 67-year-old man, 15 years post–living related kidney transplant developed a cutaneous squamous cell carcinoma (SCC). Surveillance positron emission tomography/computed tomography scan for SCC identified an ischial bone lesion. Immunoglobulin A λ paraproteins were found on serum protein electrophoresis/urine protein electrophoresis. Bone marrow biopsy and aspirate were normocellular, but displayed multifocal clusters of large binucleated and multinucleated plasma cells with variable histiocytoid or Hodgkin/Reed-Sternberg cell–like cytomorphology (panel A [hematoxylin and eosin stain, original magnification ×1000]; panels B-C [Wright-Giemsa stain, original magnification ×500]), ∼20% of marrow cellularity, and immunophenotype: CD45, CD138+ (panel D; CD138 stain, original magnification ×500), CD19, CD20, CD117, CD27+, CD28+, CD56(weak)+ (panel E; CD56 stain, original magnification ×500), cyclin D1 and CD30, with λ light-chain restriction (panel F; in situ hybridization for lambda mRNA stain, original magnification ×500). Epstein-Barr virus (EBV)-encoded RNA–in situ hybridization was negative. Fluorescence in situ hybridization analysis revealed monosomy 13, loss of 1 copy of the immunoglobulin heavy chain gene, and 1q21 (CKS1B) gain; subclones showed monosomy 17 and 1p32 (CDKN2C) deletion.

This case represents a monomorphic posttransplant lymphoproliferative disorder (PTLD)–plasma cell myeloma (PCM), which accounts for ∼5% of all PTLD (prevalence ∼1/1000 solid organ transplant recipients). Posttransplant (PT)-PCM usually occurs late after transplantation, in older individuals (median age, 60 years), recipients of deceased donor allografts, and in those having received antithymocyte globulin therapy. Most are EBV and cytogenetic abnormalities are similar to immunocompetent multiple myeloma. Reduction of immunosuppression is not efficacious in PT-PCM, but use of modern myeloma therapeutic regimens has led to significantly improved outcomes.

Close modal

For additional images, visit the ASH Image Bank, a reference and teaching tool that is continually updated with new atlas and case study images. For more information, visit http://imagebank.hematology.org.

Sign in via your Institution